Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
336.89M | 186.37M | 77.06M | 19.14M | 0.00 |
Gross Profit | ||||
255.25M | 139.34M | 64.69M | 17.23M | -623.00K |
EBIT | ||||
-87.61M | -109.15M | -131.22M | -173.41M | -104.30M |
EBITDA | ||||
-48.97M | -136.49M | -122.41M | -65.39M | -102.31M |
Net Income Common Stockholders | ||||
-87.94M | -163.41M | -135.66M | -83.99M | -103.27M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
280.31M | 286.33M | 251.72M | 156.54M | 231.82M |
Total Assets | ||||
670.75M | 646.62M | 352.91M | 294.65M | 240.86M |
Total Debt | ||||
317.76M | 308.14M | 2.19M | 2.61M | 3.26M |
Net Debt | ||||
95.26M | 21.82M | -25.82M | -28.73M | -138.82M |
Total Liabilities | ||||
445.11M | 397.95M | 210.87M | 174.44M | 68.77M |
Stockholders Equity | ||||
225.64M | 248.67M | -392.82M | 120.21M | -173.17M |
Cash Flow | Free Cash Flow | |||
9.33M | -91.05M | -120.41M | -151.78M | -89.30M |
Operating Cash Flow | ||||
10.32M | -70.94M | -120.14M | -132.76M | -89.08M |
Investing Cash Flow | ||||
-90.13M | -107.20M | 7.70M | 48.55M | 37.87M |
Financing Cash Flow | ||||
17.70M | 336.60M | 109.09M | 73.47M | 181.29M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
67 Neutral | $2.16B | 240.03 | 4.00% | ― | 20.10% | ― | |
54 Neutral | $1.54B | ― | -36.38% | ― | -40.11% | -17.79% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
48 Neutral | $2.12B | ― | -37.08% | ― | 80.76% | 53.98% | |
48 Neutral | $1.92B | ― | -34.40% | ― | ― | 7.97% | |
46 Neutral | $1.76B | ― | -43.94% | ― | -83.18% | -144.95% | |
36 Underperform | $2.33B | ― | -25.24% | ― | ― | -147.80% |
Mirum Pharmaceuticals reported preliminary net product sales of approximately $336 million for 2024, surpassing the guidance range. The company projects 2025 global net product sales between $420 million and $435 million, highlighting its growth and leadership in rare diseases with significant advancements in treatments such as volixibat and potential new therapies for conditions like Fragile X Syndrome.